Aaron N. Hata

May 1, 2024 | jci.org | Gordon Mills |Marilyne Labrie |Kyle Vaccaro |Aaron N. Hata

AbstractTargeting tumor-associated macrophages (TAMs) is an emerging approach being tested in multiple clinical trials. TAMs, depending on their differentiation state, can exhibit pro- or antitumorigenic functions. For example, the M2-like phenotype represents a protumoral state that can stimulate tumor growth, angiogenesis, metastasis, therapy resistance, and immune evasion by expressing immune checkpoint proteins.

Apr 8, 2024 | cell.com | Aaron N. Hata |Mani Larijani |Simon FRASER

APOBEC3 cytidine deaminases have emerged as key drivers of mutagenesis in a wide spectrum of tumor types and are now appreciated to play a causal role in driving tumor evolution and drug resistance. As efforts to develop APOBEC3 inhibitors progress, understanding the timing and consequences of APOBEC3-mediated mutagenesis in distinct clinical contexts will be critical for guiding the development of anti-cancer therapeutic strategies.

Dec 4, 2023 | nature.com | Shahabbedin Sotudian |Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio | +14 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02605-z, published online 21 October 2023. This article was originally published under a standard Springer Nature license (© The Author(s), under exclusive licence to Springer Nature America, Inc.); it is now available as an open-access paper under a Creative Commons Attribution 4.0 International license, © The Author(s). The error has been corrected in the HTML and PDF versions of the article.

Oct 21, 2023 | nature.com | Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio |William D Figg | +14 more

AbstractAlthough circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma.